BNP Paribas Knock-Out 6MK/ DE000PD35F02 /
2024-05-16 2:21:00 PM | Chg.+0.040 | Bid2:34:17 PM | Ask2:34:17 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.050EUR | +1.00% | 4.090 Bid Size: 12,000 |
4.210 Ask Size: 12,000 |
MERCK CO. D... | 88.3167 - | 2078-12-31 | Call |
GlobeNewswire
12:00 AM
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-15
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VIS...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-12-05
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA